



Supplementary Materials

Table S1. Cutoff values for fibrosis assessments.

	Low Risk for Advanced Fibrosis	Indeterminate Risk for Advanced Fibrosis	High Risk for Advanced Fibrosis	Reference
Fib-4	<1.3	1.3–2.67	>2.67	Kanwal, F.; Shubrook, J.H.; Adams, L.A.; et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. <i>Gastroenterology</i> 2021, 161, 1657–1669 [1].
	≤1.3	1.3–3.25	>3.25	Newsome, P.N.; Cramb, R.; Davison, S.M.; et al. Guidelines on the management of abnormal liver blood tests. <i>Gut</i> 2018, 67, 6–19 [2].
	≤2.67	≤2.67	>2.67	National Institute for Health and Care Excellence. How should I assess a person with NAFLD? Available online (accessible only in the UK): https://cks.nice.org.uk/topics/non-alcoholic-fatty-liver-disease-nafld/diagnosis/assessment/#:~:text=Fibrosis%20%28FIB%29-4%20Score%20%28FIB-4%29%20%E2%80%94%20a%20score%20of,a%20hepatology%20specialist%20for%20further%20assessment%20and%20management (accessed 3 April 2023) [3].
	<1.6	1.6–3.6	>3.6	Kim, B.K.; Kim, D.Y.; Park, J.Y.; et al. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. <i>Liver Int.</i> 2010, 30, 546–553 [4].
NFS	≤−1.455	−1.455–0.675	>0.675	Newsome, P.N.; Cramb, R.; Davison, S.M.; et al. Guidelines on the management of abnormal liver blood tests. <i>Gut</i> 2018, 67, 6–19 [2].
	<−1.455	−1.455–0.676	>0.676	Angulo, P.; Hui, J.M.; Marchesini, G.; et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. <i>Hepatology</i> 2007, 45, 846–854 [5].
	≤−1.455	>−1.455	>−1.455	National Institute for Health and Care Excellence. How should I assess a person with NAFLD? Available online: https://cks.nice.org.uk/topics/non-alcoholic-fatty-liver-disease-nafld/diagnosis/assessment/#:~:text=Fibrosis%20%28FIB%29-4%20Score%20%28FIB-4%29%20%E2%80%94%20a%20score%20of,a%20hepatology%20specialist%20for%20further%20assessment%20and%20management (accessed 3 April 2023) [3].
ELF™	≤9.5		>9.5	Newsome, P.N.; Cramb, R.; Davison, S.M.; et al. Guidelines on the management of abnormal liver blood tests. <i>Gut</i> 2018, 67, 6–19 [2].
	<10.5	<10.5	≥10.51	National Institute for Health and Care Excellence. How should I assess a person with NAFLD? Available online: https://cks.nice.org.uk/topics/non-alcoholic-fatty-liver-disease-nafld/diagnosis/assessment/#:~:text=Fibrosis%20%28FIB%29-4%20Score%20%28FIB-4%29%20%E2%80%94%20a%20score%20of,a%20hepatology%20specialist%20for%20further%20assessment%20and%20management (accessed 3 April 2023) [3].
	<7.7	≥7.7–<9.8	≥9.8	Siemens Healthineers. The enhanced liver fibrosis (ELF) blood test: literature compendium volume 1. Available online: https://www.siemens-healthineers.com/en-uk/laboratory-diagnostics/assays-by-diseases-conditions/liver-disease/elf-test (accessed 3 April 2023) [6].
VCTE	<8 kPa	8–12 kPa	>12 kPa	Kanwal, F.; Shubrook, J.H.; Adams, L.A.; et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. <i>Gastroenterology</i> 2021, 161, 1657–1669 [1].
	≤8.2 kPa ^a		>8.2 kPa ^a	Eddowes, P.J.; Sasso, M.; Allison, M.; et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. <i>Gastroenterology</i> 2019, 156, 1717–1730 [7].

≤7.8 kPa	>7.8 kPa or invalid scan	Newsome, P.N.; Cramb, R.; Davison, S.M.; et al. Guidelines on the management of abnormal liver blood tests. <i>Gut</i> 2018, <i>67</i> , 6–19 [2].
----------	--------------------------------	--

^a Youden's index cutoff value of >8.2 kPa is the threshold for ≥fibrosis stage 2, representing clinically significant fibrosis. ELFTM, enhanced liver fibrosis; Fib-4, Fibrosis-4; NFS, NAFLD fibrosis score; VCTE, vibration controlled transient elastography.

References

1. Kanwal, F.; Shubrook, J.H.; Adams, L.A.; Pfothenauer, K.; Wong, V.W.; Wright, E.; Abdelmalek, M.F.; Harrison, S.A.; Loomba, R.; Mantzoros, C.S.; et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. *Gastroenterology* **2021**, *161*, 1657–1669. <https://doi.org/10.1053/j.gastro.2021.07.049>.
2. Newsome, P.N.; Cramb, R.; Davison, S.M.; Dillon, J.F.; Foulerton, M.; Godfrey, E.M.; Hall, R.; Harrower, U.; Hudson, M.; Langford, A.; et al. Guidelines on the management of abnormal liver blood tests. *Gut* **2018**, *67*, 6–19. <https://doi.org/10.1136/gutjnl-2017-314924>.
3. National Institute for Health and Care Excellence. How should I assess a person with NAFLD? Available online (accessible only in the UK): <https://cks.nice.org.uk/topics/non-alcoholic-fatty-liver-disease-nafl/diagnosis/assessment/#:~:text=Fibrosis%20%28FIB%29-4%20Score%20%28FIB-4%29%20%E2%80%94%20a%20score%20of,a%20hepatology%20specialist%20for%20further%20assessment%20and%20management> (accessed 3 April 2023).
4. Kim, B.K.; Kim, D.Y.; Park, J.Y.; Ahn, S.H.; Chon, C.Y.; Kim, J.K.; Paik, Y.H.; Lee, K.S.; Park, Y.N.; Han, K.H. Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. *Liver Int* **2010**, *30*, 546–553. <https://doi.org/10.1111/j.1478-3231.2009.02192.x>.
5. Angulo, P.; Hui, J.M.; Marchesini, G.; Bugianesi, E.; George, J.; Farrell, G.C.; Enders, F.; Saksena, S.; Burt, A.D.; Bida, J.P.; et al. The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD. *Hepatology* **2007**, *45*, 846–854. <https://doi.org/10.1002/hep.21496>.
6. Siemens Healthineers. The enhanced liver fibrosis (ELF) blood test: Literature compendium volume 1. Available online: <https://www.siemens-healthineers.com/en-uk/laboratory-diagnostics/assays-by-diseases-conditions/liver-disease/elf-test> (accessed 3 April 2023).
7. Eddowes, P.J.; Sasso, M.; Allison, M.; Tsochatzis, E.; Anstee, Q.M.; Sheridan, D.; Guha, I.N.; Cobbold, J.F.; Deeks, J.J.; Paradis, V.; et al. Accuracy of FibroScan controlled attenuation parameter and liver stiffness measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease. *Gastroenterology* **2019**, *156*, 1717–1730. <https://doi.org/10.1053/j.gastro.2019.01.042>.